Vanguard Portfolio Management
TRVI icon

Vanguard Portfolio Management’s Trevi Therapeutics TRVI Stock Holding History

Vanguard Portfolio Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Buy
1,176,872
+208,284
+22% +$3.03M ﹤0.01% 1958
2026
Q1 		$11.6M Buy
+968,588
New +$10.8M ﹤0.01% 2070

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Portfolio Management's TRVI Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Trevi Therapeutics (TRVI) stake by 22% in Q2 2026, buying an estimated $3.03M and bringing the position to 1,176,872 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

Vanguard Portfolio Management first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Vanguard Portfolio Management held 1,176,872 shares of Trevi Therapeutics worth $21.9M as of Q2 2026.
  • Vanguard Portfolio Management bought 208,284 Trevi Therapeutics shares in Q2 2026, an estimated $3.03M.
  • Trevi Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1958 holding.
  • Vanguard Portfolio Management first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.